Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ciprian Tomuleasa, Cristina Selicean, Sonia Cismas, Anca Jurj, Mirela Marian, Delia Dima, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Anna Vischer, Kanza Arifeen, Sonia Selicean, Mihnea Zdrenghea, Horia Bumbea, Alina Tanase, Ravnit Grewal, Laura Pop, Carmen Aanei & Ioana Berindan-Neagoe. (2018) Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. Critical Reviews in Clinical Laboratory Sciences 55:5, pages 329-345.
Read now
Read now
Marco Montillo, Timo Schinkoethe & Thomas Elter. (2005) Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome. Cancer Investigation 23:6, pages 488-496.
Read now
Read now
C. Darrell Jennings & Kenneth A. Foon. (1997) Flow Cytometry: Recent Advances in Diagnosis and Monitoring of Leukemia. Cancer Investigation 15:4, pages 384-399.
Read now
Read now
M. Keating, B. Cheson, J. G. Gribben, B. Robertson & L. Nadler. (1996) Innovative Strategies for the Treatment of CLL. Leukemia & Lymphoma 22:sup2, pages 53-64.
Read now
Read now
R. H. Scheuermann & E. Racila. (1995) CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy. Leukemia & Lymphoma 18:5-6, pages 385-397.
Read now
Read now
Deborah S. Richardson, Stephen A. Johnson, John A. Hopkins, Denise Howe & Malcolm J. Phillips. (1994) Absence of Minimal Residual Disease Detectable by Facs, Southern Blot or PCR in Patients with Chronic Lymphocytic Leukaemia Treated with Fludarabine. Acta Oncologica 33:6, pages 627-630.
Read now
Read now
French Cooperative Group on Chronic Lymphocytic Leukemia. (1991) Unresolved Issues in Chronic Lymphocytic Leukemia Treatment. Leukemia & Lymphoma 5:sup1, pages 79-81.
Read now
Read now
Articles from other publishers (32)
Giovanni Riva, Vincenzo Nasillo, Anna Maria Ottomano, Giuliano Bergonzini, Ambra Paolini, Fabio Forghieri, Beatrice Lusenti, Patrizia Barozzi, Ivana Lagreca, Stefania Fiorcari, Silvia Martinelli, Rossana Maffei, Roberto Marasca, Leonardo Potenza, Patrizia Comoli, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti & Mario Luppi. (2021) Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers 13:18, pages 4582.
Crossref
Crossref
Silvia Heltai, Paolo Ghia & Lydia Scarfò. (2019) Relevance of Minimal Residual Disease in the Era of Targeted Agents. The Cancer Journal 25:6, pages 410-417.
Crossref
Crossref
Paolo Ghia & Andy Rawstron. (2018) Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. Leukemia 32:6, pages 1307-1316.
Crossref
Crossref
Yu.V. Mirolyubova, E.A. Stadnik, V.V. Strugov, T.O. Andreeva, T.S. Nikulina, Yu.V. Virts, P.A. Butylin, A.G. Rumyantsev & A.Y. Zaritskey. (2018) Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. Clinical oncohematology 11:2, pages 167-174.
Crossref
Crossref
Mir Basharath Alikhan & Girish Venkataraman. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
79
98
.
Philip A. Thompson & William G. Wierda. (2016) Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood 127:3, pages 279-286.
Crossref
Crossref
Sebastian B?ttcher, Michael Hallek, Matthias Ritgen & Michael Kneba. (2013) The Role of Minimal Residual Disease Measurements in the Therapy for CLL. Hematology/Oncology Clinics of North America 27:2, pages 267-288.
Crossref
Crossref
M. M. Sartor & D. J. Gottlieb. (2013) A single tube 10‐color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytometry Part B: Clinical Cytometry 84B:2, pages 96-103.
Crossref
Crossref
A C Rawstron, S Böttcher, R Letestu, N Villamor, C Fazi, H Kartsios, R M de Tute, J Shingles, M Ritgen, C Moreno, K Lin, A R Pettitt, M Kneba, E Montserrat, F Cymbalista, M Hallek, P Hillmen & P Ghia. (2012) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27:1, pages 142-149.
Crossref
Crossref
Paolo Ghia. (2012) A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?. Hematology 2012:1, pages 97-104.
Crossref
Crossref
Andy C Rawstron. (2011) Occult B-cell lymphoproliferative disorders. Histopathology 58:1, pages 81-89.
Crossref
Crossref
Carol Moreno, Matthias Ritgen & Andy Rawstron. (2010) Is MRD eradication a desirable goal in CLL?. Best Practice & Research Clinical Haematology 23:1, pages 97-107.
Crossref
Crossref
Andy C. Rawstron. (2009) Monoclonal B-cell lymphocytosis. Hematology 2009:1, pages 430-439.
Crossref
Crossref
Thomas Elter, Barbara F. Eichhorst & Clemens-Martin Wendtner. (2008) Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons. Current Hematologic Malignancy Reports 4:1, pages 43-46.
Crossref
Crossref
Andy C. Rawstron & Peter Hillmen. (2008) Assessing minimal residual disease in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports 3:1, pages 47-53.
Crossref
Crossref
Hazem A. Sayala, Andy C. Rawstron & Peter Hillmen. (2007) Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Practice & Research Clinical Haematology 20:3, pages 499-512.
Crossref
Crossref
Tasneem Motiwala, Sarmila Majumder, Huban Kutay, David Spencer Smith, Donna S. Neuberg, David M. Lucas, John C. Byrd, Michael Grever & Samson T. Jacob. (2007) Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia. Clinical Cancer Research 13:11, pages 3174-3181.
Crossref
Crossref
A C Rawstron, N Villamor, M Ritgen, S Böttcher, P Ghia, J L Zehnder, G Lozanski, D Colomer, C Moreno, M Geuna, P A S Evans, Y Natkunam, S E Coutre, E D Avery, L Z Rassenti, T J Kipps, F Caligaris-Cappio, M Kneba, J C Byrd, M J Hallek, E Montserrat & P Hillmen. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:5, pages 956-964.
Crossref
Crossref
Michael J. Keating, Nicholas Chiorazzi, Bradley Messmer, Rajendra N. Damle, Steven L. Allen, Kanti R. Rai, Manlio Ferrarini & Thomas J. Kipps. (2003) Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology 2003:1, pages 153-175.
Crossref
Crossref
Karim Maloum, Laurent Sutton, Sylvie Baudet, Caroline Laurent, Patrick Bonnemye, Christian Magnac & Hélène Merle‐Béral. (2002)
Novel flow‐cytometric analysis based on BCD5
+
subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia
. British Journal of Haematology 119:4, pages 970-975.
Crossref
Crossref
E Giné, F Bosch, N Villamor, M Rozman, D Colomer, A López-Guillermo, E Campo & E Montserrat. (2002) Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. Leukemia 16:8, pages 1454-1459.
Crossref
Crossref
Ranjit Thomas, Isabel Ribeiro, Patricia Shepherd, Peter Johnson, Margaret Cook, Anil Lakhani, Richard Kaczmarski, Patrick Carrington & Daniel Catovsky. (2002) Spontaneous clinical regression in chronic lymphocytic leukaemia. British Journal of Haematology 116:2, pages 341-345.
Crossref
Crossref
Andy C. RawstronBen KennedyPaul A. S. EvansFaith E. DaviesStephen J. RichardsAndy P. HaynesNigel H. RussellGeoff HaleGareth J. MorganAndrew S. JackPeter Hillmen. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:1, pages 29-35.
Crossref
Crossref
J Esteve, N Villamor, D Colomer, F Cervantes, E Campo, E Carreras & E Montserrat. (2001) Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15:3, pages 445-451.
Crossref
Crossref
Estella Matutes & Aaron Polliack. (2001) Morphological and Immunophenotypic Features of Chronic Lymphocytic Leukemia. Reviews in Clinical and Experimental Hematology 4:1, pages 22-47.
Crossref
Crossref
C. Darrell JenningsKenneth A. Foon. (1997) Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. Blood 90:8, pages 2863-2892.
Crossref
Crossref
Branimir Jaksic, Maura Brugiatelli, Ivo Krc, Hajna Losonczi, Jerzy Holowiecki, Ana Planinc-Peraica, Rajko Kusec, Fortunato Morabito, Pasquale Iacopino & Dieter Lutz. (1997) High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Cancer 79:11, pages 2107-2114.
Crossref
Crossref
N. Bardin, M. Mutin & G. Lesaule. (1996) 4. Analyse des cellules endothèliales. Revue Française des Laboratoires 1996:287, pages 96-100.
Crossref
Crossref
Carlton C. Stewart. (1996) Residual disease detection in acute myeloid leukemia. Clinical Immunology Newsletter 16:10-11, pages 147-151.
Crossref
Crossref
Stefano Molica, Maura Brugiatelli, Vincenzo Callea, Fortunato Morabito, Domenico Levato, Francesco Nobile & Antonio Alberti. (2009) Comparison of younger versus older B‐cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. European Journal of Haematology 52:4, pages 216-221.
Crossref
Crossref
Robert Peter Gale & Emilio Montserrat. (1993) 8 Intensive therapy of chronic lymphocytic leukaemia. Baillière's Clinical Haematology 6:4, pages 879-885.
Crossref
Crossref
Susan B. Wormsley & Nissi M. Varki. (1993) Immunophenotypic characterization of chronic lymphoproliferative disorders. Clinical Immunology Newsletter 13:5-6, pages 60-66.
Crossref
Crossref